ES2153434T3 - Inhibidores de la proteasa del vih y sus intermedios. - Google Patents

Inhibidores de la proteasa del vih y sus intermedios.

Info

Publication number
ES2153434T3
ES2153434T3 ES94931802T ES94931802T ES2153434T3 ES 2153434 T3 ES2153434 T3 ES 2153434T3 ES 94931802 T ES94931802 T ES 94931802T ES 94931802 T ES94931802 T ES 94931802T ES 2153434 T3 ES2153434 T3 ES 2153434T3
Authority
ES
Spain
Prior art keywords
hiv
intermediates
inhibitors
proteasa
hiv protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94931802T
Other languages
English (en)
Inventor
William Joseph Hornback
John Edwin Munroe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2153434T3 publication Critical patent/ES2153434T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

ESTA INVENCION CONSISTE EN INHIBIDORES DE LA PROTEASA DEL VIH Y EN INTERMEDIARIOS PARA PREPARAR INHIBIDORES DE LA PROTEASA DEL VIH. LA ENZIMA PROTEASA DEL VIH REPRESENTA UN BLANCO VIABLE PARA LA INHIBICION DE LA REPLICACION VIRAL DEL VIH, PROPORCIONANDO ASI UN METODO PARA EL TRATAMIENTO O LA PREVENCION DE LAS INFECCIONES POR VIH.
ES94931802T 1994-02-02 1994-10-06 Inhibidores de la proteasa del vih y sus intermedios. Expired - Lifetime ES2153434T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19080994A 1994-02-02 1994-02-02

Publications (1)

Publication Number Publication Date
ES2153434T3 true ES2153434T3 (es) 2001-03-01

Family

ID=22702879

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94931802T Expired - Lifetime ES2153434T3 (es) 1994-02-02 1994-10-06 Inhibidores de la proteasa del vih y sus intermedios.

Country Status (14)

Country Link
US (1) US5734057A (es)
EP (1) EP0746320B1 (es)
JP (1) JPH09508416A (es)
AT (1) ATE198985T1 (es)
AU (1) AU8074894A (es)
BR (1) BR9408531A (es)
CA (1) CA2182090A1 (es)
DE (1) DE69426655T2 (es)
DK (1) DK0746320T3 (es)
ES (1) ES2153434T3 (es)
GR (1) GR3035716T3 (es)
HU (1) HUT74685A (es)
PT (1) PT746320E (es)
WO (1) WO1995020965A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
JP4921466B2 (ja) * 2005-07-12 2012-04-25 マサチューセッツ インスティテュート オブ テクノロジー 無線非放射型エネルギー転送
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2014007951A2 (en) 2012-06-13 2014-01-09 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102469849B1 (ko) 2013-04-19 2022-11-23 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2395271A1 (fr) * 1977-06-21 1979-01-19 Parcor Procede de preparation de thieno (2,3-c) et thieno (3,2-c) pyridines
US4749692A (en) * 1977-06-22 1988-06-07 Sanofi, S.A. Therapeutic compositions having anti-thrombotic and anti-blood-platelet-aggregating activity
FR2397417A1 (fr) * 1977-07-12 1979-02-09 Parcor Procede de preparation de derives de la thienopyridine
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
US5026700A (en) * 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
US5232928A (en) * 1989-07-25 1993-08-03 Boehringer Ingelheim Pharmaceuticals, Inc. Tetrahydroisoquinoline amides
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
ATE164839T1 (de) * 1990-11-19 1998-04-15 Monsanto Co Retrovirale proteaseinhibitoren
AU647239B2 (en) * 1991-02-08 1994-03-17 Sankyo Company Limited New beta-amino- alpha-hydroxycarboxylic acids and their use
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
WO1993013066A1 (en) * 1991-12-20 1993-07-08 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors

Also Published As

Publication number Publication date
EP0746320A4 (en) 1997-06-11
HUT74685A (en) 1997-01-28
AU8074894A (en) 1995-08-21
DK0746320T3 (da) 2001-02-19
JPH09508416A (ja) 1997-08-26
BR9408531A (pt) 1997-08-05
WO1995020965A1 (en) 1995-08-10
CA2182090A1 (en) 1995-08-10
HU9602106D0 (en) 1996-09-30
ATE198985T1 (de) 2001-02-15
PT746320E (pt) 2001-05-31
DE69426655T2 (de) 2001-06-13
GR3035716T3 (en) 2001-07-31
DE69426655D1 (de) 2001-03-08
EP0746320B1 (en) 2001-01-31
EP0746320A1 (en) 1996-12-11
US5734057A (en) 1998-03-31

Similar Documents

Publication Publication Date Title
ES2153434T3 (es) Inhibidores de la proteasa del vih y sus intermedios.
HU9603328D0 (en) Retroviral protease inhibitor combinations
MY131388A (en) Inhibitors of hiv protease useful for the treatment of aids.
NO893400D0 (no) Hiv protease inhibitorer egnet for behandling av aids.
NO905428D0 (no) Fremgangsmaate for fremstilling av hiv-proteaseinhibitorerfor behandling av aids.
NO963860L (no) Isoprenyl-transferase-inhibitorer
NO932620L (no) Amindiol-proteaseinhibitorer
PT810209E (pt) Hidroxietilamino-sulfonamidas de alfa- e beta-aminoacidos uteis como inibidores de protease retroviral
ES2139195T3 (es) Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
MD1507G2 (ro) Inhibitori, compoziţie farmaceutică pe baza lor şi procedeu de inhibare a HIV proteazei
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
AP9200410A0 (en) Retroviral protease inhibitors.
ES2051641A1 (es) Procedimientos para la preparacion de compuestos derivados de tiourea.
DE69414708T2 (de) Verbindungen und methoden zur inhibition von hiv und verwandten viren
DK0804410T3 (da) Fremgangsmåde til fremstilling af retrovirale proteaseinhibitor-mellemprodukter
MY132553A (en) Methods of making hiv-protease inhibitors and intermediates for making hiv-protease inhibitors
BR9808923B1 (pt) processos para fazer compostos inibidores de ciclooxigenase-2, e, compostos intermediÁrios para fazer inibidores de ciclooxigenase-2.
MX9704024A (es) Composicion y metodo para la prevencion y el tratamiento de infeccion con vih-1.
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
MX9207384A (es) Estearasa de p-nitrobencilo purificada y procedimiento para su obtencion.
DK0817786T3 (da) Substituerede tetronsyrer, der er nyttige til behandling af HIV og andre retrovira
YU11599A (sh) Intermedijari za pravljenje inhibitora hiv-proteaze i postupci za pravljenje inhibitora hiv-proteaze
DE58907215D1 (de) Industrieofen, insbesondere Einkammer-Vakuumofen, zur Wärmebehandlung metallischer Werkstücke.
DE3464599D1 (de) Alpha-allenic-alpha-amino acids
ES2155515T3 (es) Derivados de difluorostatona macrociclica utiles como agentes antivirales.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 746320

Country of ref document: ES